Company profile
Cardio Diagnostics Holdings, Inc.
NASDAQ: CDIO · Healthcare · Biotechnology
#1122 of 1,417 Healthcare companies by revenuebottom-quartile growth
EA Score
30DFH 32DQ 23GM 40SS 30
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, balance-sheet leverage · ↓ Piotroski F, operating margin
Methodology →Revenue TTM
$14.4k
Rev growth YoY (TTM)
-25.9%
Net income (FY)
-$6.5M
Employees
15
as of 2026-08-24
Market cap
$6.0M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$14.8k$14.8k2025
Net income-$6.5M-$6.5M2025
Operating income-$6.5M-$6.5M2025
Total assets$7.8M$7.8M2025
Liabilities$793.1k$793.1k2025
Equity$7.0M$7.0M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Cardio Diagnostics Holdings, Inc.’s revenue?
Cardio Diagnostics Holdings, Inc. booked $14.8k in FY2025 revenue, contracting 58% year over year — slower than 84% of Healthcare companies we track, at a -43832.5% net margin.
Peers · Healthcare
Gemina Laboratories Ltd.——Upper Street Marketing Inc.——Pineapple, Inc.——Navidea Biopharmaceuticals, Inc.——Nass Valley Gateway Ltd.——Premier Biomedical, Inc.——Neighbors
Cook →Key facts
CEOMeeshanthini V. Dogan
SectorHealthcare
IndustryBiotechnology
HeadquartersChicago, IL
ExchangeNASDAQ: CDIO
Employees15
IPO date2022-01-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.